Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1996 2
1997 3
1998 3
1999 1
2004 1
2007 2
2010 1
2011 1
2016 1
2017 1
2018 1
2020 1
2021 1
2022 3
2023 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, Hirai S, Ishida M, Kawachi H, Sawada R, Tachibana Y, Osoegawa A, Horinaka M, Sakai T, Yasuhiro T, Kozaki R, Yano S, Takayama K. Nakamura R, et al. Among authors: yasuhiro t. Cancer Lett. 2024 Aug 28;598:217124. doi: 10.1016/j.canlet.2024.217124. Epub 2024 Jul 24. Cancer Lett. 2024. PMID: 39059573 Free article.
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia.
Post SM, Ma H, Malaney P, Zhang X, Aitken MJL, Mak PY, Ruvolo VR, Yasuhiro T, Kozaki R, Chan LE, Ostermann LB, Konopleva M, Carter BZ, DiNardo C, Andreeff MD, Khoury JD, Ruvolo PP. Post SM, et al. Among authors: yasuhiro t. Haematologica. 2022 Jun 1;107(6):1311-1322. doi: 10.3324/haematol.2021.278369. Haematologica. 2022. PMID: 34732043 Free PMC article.
Linear Basal cell carcinoma in an asian patient.
Shinsuke K, Hirohiko K, Yasuhiro T, Kazuo H, Masayoshi I. Shinsuke K, et al. Among authors: yasuhiro t. Open Ophthalmol J. 2007 Dec 17;1:20-2. doi: 10.2174/1874364100701010020. Open Ophthalmol J. 2007. PMID: 19478861 Free PMC article.
ONO-8590580, a Novel GABAAα5 Negative Allosteric Modulator Enhances Long-Term Potentiation and Improves Cognitive Deficits in Preclinical Models.
Kawaharada S, Nakanishi M, Nakanishi N, Hazama K, Higashino M, Yasuhiro T, Lewis A, Clark GS, Chambers MS, Maidment SA, Katsumata S, Kaneko S. Kawaharada S, et al. Among authors: yasuhiro t. J Pharmacol Exp Ther. 2018 Jul;366(1):58-65. doi: 10.1124/jpet.117.247627. Epub 2018 Apr 19. J Pharmacol Exp Ther. 2018. PMID: 29674331
Clinical impact of preoperative serum p53 antibody titers in 1487 patients with surgically treated esophageal squamous cell carcinoma: a multi-institutional study.
Takashi S, Satoshi Y, Akihiko O, Naoya Y, Yusuke T, Kentaro M, Yu O, Yasuaki N, Koichi Y, Takashi F, Ryo O, Isamu H, Chikara K, Kosuke N, Yasuhiro T, Kazuhiko Y, Hideaki S. Takashi S, et al. Among authors: yasuhiro t. Esophagus. 2021 Jan;18(1):65-71. doi: 10.1007/s10388-020-00761-6. Epub 2020 Jul 26. Esophagus. 2021. PMID: 32715348
Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.
Yasuhiro T, Sawada W, Klein C, Kozaki R, Hotta S, Yoshizawa T. Yasuhiro T, et al. Leuk Lymphoma. 2017 Mar;58(3):699-707. doi: 10.1080/10428194.2016.1201567. Epub 2016 Aug 9. Leuk Lymphoma. 2017. PMID: 27684575
22 results